%0 Journal Article
%T Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
%A Goodman JJ
%A Martin SI
%J Therapeutics and Clinical Risk Management
%D 2012
%I 
%R http://dx.doi.org/10.2147/TCRM.S17413
%X itical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections Review (2679) Total Article Views Authors: Goodman JJ, Martin SI Published Date March 2012 Volume 2012:8 Pages 149 - 156 DOI: http://dx.doi.org/10.2147/TCRM.S17413 Received: 25 January 2012 Accepted: 20 February 2012 Published: 26 March 2012 Julian J Goodman, Stanley I Martin Division of Infectious Diseases, The Ohio State University, Columbus, OH, USA Abstract: Ceftaroline is a novel broad-spectrum cephalosporin  -lactam antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) as well as multidrug-resistant Streptococcus pneumoniae among other routine Gram positive and Gram negative organisms. It has been approved by the US Food and Drug Administration for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (ABSSSIs). Ceftaroline is approved for treatment of ABSSSI due to MRSA, however currently there are no data for pneumonia due to MRSA in humans. Herein we review the major clinical trials as well as ceftaroline microbiology, pharmacokinetics, and safety, followed by a look at further directions for investigation of this new agent.
%K ceftaroline
%K pneumonia
%K skin infection
%U https://www.dovepress.com/critical-appraisal-of-ceftaroline-in-the-management-of-community-acqui-peer-reviewed-article-TCRM